EUVIMEDEUVIMED entdecken
Crossref

Desmethoxyyangonin, a Potent Cannabinoid Receptor 2 Agonist, Alleviates Bone Loss in Ovariectomized Mice via Dual Regulation of Osteoblast and Osteoclast Function

Gidion Wilson Mening'oo iD, Hui Yuan, Mei Wang, Weibiao Wang iD, Fen Ma, Weiman Zhang, Jinggui Ma, Jianyu Chen iD, Yiping Jiang, Xueqin Ma iD

Phytotherapy Research · 2026

DOI: 10.1002/ptr.70232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytotherapy Research, 2026. Verfasst von Gidion Wilson Mening'oo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Analysis, School of Pharmacy; Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Medica…. Hauptthemen laut MEDLINE: Osteoclasts, Receptor, Cannabinoid, CB2, Osteoblasts, Osteoporosis. Die Arbeit nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Ningxia Natural Science Foundation of China, Key Research and Invention Program of Ningxia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoporosis is a prevalent skeletal disorder characterized by imbalanced bone remodeling, leading to excessive bone loss. Cannabinoid receptor 2 (CB2) has emerged as a promising therapeutic target in bone metabolism due to its peripheral expression and dual regulation of osteoblast and osteoclast activity. Desmethoxyyangonin (DMY) has demonstrated CB2 agonist activity, yet its therapeutic efficacy and molecular mechanisms in bone remain incompletely understood. Here, we investigated the anti‐osteoporotic effects of DMY and its mechanistic insight on CB2 signaling. An ovariectomized (OVX) mouse model was used to assess the in vivo effects of DMY on trabecular bone microarchitecture and biomechanical properties. The impact of DMY on osteoblast and osteoclast differentiation was examined in vitro using MC3T3‐E1 cells and bone marrow‐derived macrophages (BMMs), respectively. Molecular docking and molecular dynamics simulations were conducted to investigate the potential interactions between DMY and CB2. Untargeted metabolomics was performed to explore metabolic alterations associated with DMY treatment. Western blot studies evaluated key osteogenic and signaling markers. DMY treatment significantly restored bone mineral density and improved trabecular microarchitecture. In vitro, DMY promoted osteoblast differentiation and mineralization while concurrently suppressing osteoclast formation and function. Pharmacological blockade of CB2 with its antagonist (SR144528) abrogated DMY's effects on both cell types, indicating CB2‐mediated action. Molecular docking and dynamics simulations predicted a stable interaction between DMY and CB2. Untargeted metabolomics revealed DMY‐induced shifts in metabolic pathways related to bone remodeling. Mechanistically, DMY upregulated osteogenic markers and activated PI3K/Akt and Wnt/β‐catenin signaling cascades. Collectively, these findings demonstrate that DMY exerts bone‐protective effects via CB2‐dependent modulation of bone formation and resorption, offering a dual‐target strategy for osteoporosis intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoclastsReceptor, Cannabinoid, CB2OsteoblastsOsteoporosisCannabinoid Receptor AgonistsAnimalsOvariectomyFemaleMiceMolecular Docking SimulationMice, Inbred C57BLCell DifferentiationOsteogenesisBone DensitySignal TransductionBone RemodelingBone Resorption

Stichwörter der Autor:innen

Desmethoxyyangonin (DMY)bone remodelingcannabinoid receptor 2 (CB2)kavalactoneosteoporosis

Substanzen

Receptor, Cannabinoid, CB2Cannabinoid Receptor Agonists

Autor:innen und Institutionen

  • Department of Pharmaceutical Analysis, School of Pharmacy; Key Laboratory of Hui Ethnic Medicine Modernization, Ministry of Education, Ningxia Medical University, Yinchuan, China.
  • Fujian University of Traditional Chinese Medicine, Fuzhou, China.
  • School of Pharmacy, Naval Medical University, Shanghai, China.

ORCID-Profile: Gidion Wilson Mening'oo, Weibiao Wang, Jianyu Chen, Xueqin Ma

Förderung

  • National Natural Science Foundation of China
  • Ningxia Natural Science Foundation of China
  • Key Research and Invention Program of Ningxia
  • Open competition mechanism to select the best candidates for key research projects of Ningxia Medical University

Zitieren

APA

Mening'oo, G. W., Yuan, H., Wang, M., Wang, W., Ma, F., Zhang, W., Ma, J., Chen, J., Jiang, Y., & Ma, X. (2026). Desmethoxyyangonin, a Potent Cannabinoid Receptor 2 Agonist, Alleviates Bone Loss in Ovariectomized Mice via Dual Regulation of Osteoblast and Osteoclast Function. Phytotherapy Research. https://doi.org/10.1002/ptr.70232

Vancouver

Mening'oo GW, Yuan H, Wang M, Wang W, Ma F, Zhang W, et al. Desmethoxyyangonin, a Potent Cannabinoid Receptor 2 Agonist, Alleviates Bone Loss in Ovariectomized Mice via Dual Regulation of Osteoblast and Osteoclast Function. Phytotherapy Research. 2026. doi:10.1002/ptr.70232

BibTeX
@article{Meningoo2026,
  author = {Mening'oo, Gidion Wilson and Yuan, Hui and Wang, Mei and Wang, Weibiao and Ma, Fen and Zhang, Weiman and Ma, Jinggui and Chen, Jianyu and Jiang, Yiping and Ma, Xueqin},
  title = {Desmethoxyyangonin, a Potent Cannabinoid Receptor 2 Agonist, Alleviates Bone Loss in Ovariectomized Mice via Dual Regulation of Osteoblast and Osteoclast Function},
  journal = {Phytotherapy Research},
  year = {2026},
  doi = {10.1002/ptr.70232}
}
Kostenlos starten →